Lilly Continues To Bet On Alzheimer's With Avid Acquisition
Unfazed by recent setbacks to semagacestat, Eli Lilly pays $300 million upfront to acquire a diagnostic company with a promising late-stage test for Alzheimer's disease.
Unfazed by recent setbacks to semagacestat, Eli Lilly pays $300 million upfront to acquire a diagnostic company with a promising late-stage test for Alzheimer's disease.